Huntington Bancshares Incorporated (HBAN) Stock Price Today
Aura AI Summary
Key Stats
- $36.71BMARKET_CAP
- -VOLUME
- FinancialsSECTOR
- $19.27FIFTY_TWO_WEEK_HIGH
- $15.02FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- -ENTERPRISE_VALUE
- 3.47%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Huntington Bancshares Incorporated (HBAN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Huntington Bancshares Incorporated has traded between a low of $15.02 and a high of $19.27, highlighting its annual price range. Buy and sell Huntington Bancshares Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Most Recent News
AI in Pathology market to nearly double by 2035 despite US-Israel-Iran conflict disruptions
The global AI in Pathology market, valued at $28.75 million in 2025, is projected to grow at a 9.12% CAGR to reach $68.81 million by 2035. Growth is driven by rising demand for digital pathology, AI diagnostics, and improved workflow efficiency throu...

AI data centers drive major infrastructure shifts with hyperscalers and sovereign initiatives leading growth.
The global AI data center market is rapidly expanding due to the rise of generative AI and advanced cognitive analytics, requiring purpose-built, high-density facilities with advanced cooling and networking technologies. Hyperscalers like Microsoft, ...

SKYRIZI sales hit $11.7B in 2024 with 51% growth, expanding across multiple disease indications.
SKYRIZI achieved blockbuster sales of $11.7 billion in 2024, growing 51% year-over-year, driven by approvals in psoriasis, psoriatic arthritis, and inflammatory bowel diseases like Crohn's. Its strong clinical efficacy targeting the IL-23 pathway and...
